Liraglutide-A Novel GLP-1 Analogue

Author(s): Sanjay Kalra, Bharti Kalra, Amit Sharma

Journal Name: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Continued as New Advances on Endocrine Metabolic and Immune Diseases

Volume 3 , Issue 3 , 2009


Liraglutide is a novel glucagon-like peptide 1 analogue, which shows promise as a safe, effective therapy for type 2 diabetes. This review discusses the pathophysiology of type 2 diabetes, focusing on the incretin system, and reviews the pharmacology of liraglutide. A concise discussion of preclinical and clinical data is given, highlighting the benefits of liraglutide with respect to glycaemic control, weight modulation and extraglycaemic effects. This article also review some of recent patents related to the field.

Keywords: Liraglutide, type 2 diabetes, incretins, glucagon like peptide-1 (GLP-1)

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [200 - 204]
Pages: 5
DOI: 10.2174/187221409789104719
Price: $65

Article Metrics

PDF: 4